bullish
Samsung BioLogics' Revised Valuation Based on P/B Multiple
228 Views27 Oct 2016 13:11
In another regulatory filing, Samsung BioLogics presented a revised valuation based on P/B multiple. Obviously, there are still many people who are...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Samsung BioLogics' First Trading Day - Blunders in Barron's Argument & Price Prediction10 Nov 2016
- Samsung BioLogics IPO - Why Investors Are Excited & Concerned01 Nov 2016
- Samsung BioLogics IPO Price Is Set At Highest End (₩136,000) - 3 Points to Consider28 Oct 2016
- Samsung BioLogics' Revised Valuation Based on P/B Multiple27 Oct 2016
- 3 Main Debatable Points to Be Discussed in Samsung BioLogics NDR This Week21 Oct 2016
- Samsung BioLogics IPO Part 3 - Valuation05 Oct 2016
x